SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

High Roller Technologies, Inc. is an evolving and growth-oriented iCasino and entertainment company, which engages in the business of operating an online gaming business offering casino betting games to customers. The firm also offers a wide range of games including many that are available in land-based casinos, such as blackjack, roulette, baccarat, poker, and slot machines. The company was founded by Michael Alexander Cribari and Brandon Christopher Eachus on December 21, 2021 and is headquartered in Las Vegas, NV.

High Roller Technologies Inc.

High Roller Technologies Inc

High Roller Technologies (ROLR) is currently trending with explosive trading and multiple halts after announcing a binding strategic partnership with Crypto.com/us to exclusively launch event-based prediction markets in the United States. The community is highly engaged, driving a strong short squeeze narrative and anticipating significant growth as ROLR positions itself as a pioneering player in the trillion-dollar prediction market space with a major crypto partner.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending due to robust preliminary revenue guidance for its flagship MS drug Briumvi, which is surpassing expectations for 2025 and 2026 and positioning it for potential blockbuster status. The community is actively discussing Briumvi's best-in-class profile and market share expansion, especially amidst a competitor's recent regulatory setback, while also expressing frustration over the stock's current valuation and perceived manipulation.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is trending amid multiple analyst upgrades, underscoring its strengthened position in mobile gaming advertising, the promising Vector AI platform, and new payment solutions. The community is actively debating Unity's competitive advantages in its ecosystem against rivals, with many anticipating a significant breakout fueled by these strategic initiatives.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is actively trending following recent analyst downgrades, which many in the community view as an orchestrated move to drive down share price ahead of key future developments. This has sparked a heated debate, with bullish investors aggressively buying the dip, confident in the impending R2 vehicle launch and potential for a significant market rebound.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending due to widespread discussion around a potential all-cash offer for Warner Bros. Discovery assets, with many viewing this as a strategic move to avoid dilution and signal confidence ahead of upcoming earnings. This development has ignited a fervent debate among traders; bulls foresee a significant short squeeze and rebound from recent lows, while bears express skepticism, highlighting concerns over increased debt and continued technical weakness.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is a hot topic as multiple analysts have recently reiterated or upgraded ratings and raised price targets, emphasizing its AI-powered AXON platform and expanding e-commerce presence. Despite this bullish institutional sentiment, the stock experiences significant intraday volatility, leading to active community discussions about market manipulation and the viability of buying dips or shorting rallies.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is buzzing with activity, driven by compelling clinical data for its Alpha DaRT therapy in pancreatic cancer and high anticipation for Japanese market approval. Community discussions are focused on the company's prominent presence at a major healthcare conference and emerging institutional interest, signaling a potential revaluation for its innovative precision oncology approach.

New Century Logistics (BVI) Ltd. is a holding company, which is doing business through its subsidiaries, providing air and ocean export and import freight forwarding & logistics services. It offers cargo space, cargo pick up, off-airport air cargo security screening, palletization, preparation of shipping documentation, arrangement of customs clearance to cargo handling at ports and other related services. The company was founded on April 24, 2019 and is headquartered in Hong Kong.

New Century Logistics (BVI) Ltd.

New Century Logistics

New Century Logistics (NCEW) is gaining significant attention following its strategic acquisition announcement in Asia and partnerships for innovative drone-based last-mile delivery. The community is actively discussing its extremely low share float and drawing comparisons to other "Hong Kong low float" stocks that have recently experienced substantial, volatile runs. This focus, coupled with chatter about its high short interest, positions NCEW as a speculative play within the logistics sector.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is seeing significant market activity and community buzz, fueled by an anticipated presence at the J.P. Morgan Healthcare Conference and a recent positive analyst rating. High short interest remains a key talking point, with many investors speculating about a potential short squeeze and closely watching for strategic updates regarding its Matrix-M platform. While some anticipate a major breakout, others express ongoing skepticism and frustration with management's perceived lack of execution.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending due to a wave of analyst downgrades, citing intensified AI competition and a challenging software environment that fuels fears of disruption. This has sparked a fierce debate within the community, with many viewing the stock as overvalued and anticipating further declines. Conversely, a strong contingent of investors sees the company as fundamentally sound and ridiculously oversold, presenting a prime "buy the dip" opportunity amid what they consider market overreaction and manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stephens⬆️ $PYXS $8: Micvotabart Pelidotin (MICVO) Phase 1/2 R/M HNSCC Data Preview 
$MRK $BCAX $GILD BGNE $NBTX CRBP 
 
PYXS expects to present preliminary data for their stroma targeting ADC MICVO formerly (PYX-201) by YE25. 
 
Data and clinical updates expected for the following: 
(1) preliminary data from Phase 1 monotherapy dose expansion study in 2L/3L R/M HNSCC patients (post-platinum based chemo &amp; anti-PD(L)-1 and post-EGFR &amp; anti PD(L)-1 arms), 
(2) preliminary data from Phase 1/2 combination dose escalation study of MICVO &amp; KEYTRUDA in 1L/2L+ R/M HNSCC patients, and 
(3) next steps in the clinical development plan for MICVO for R/M HNSCC. 
 
We expect PYXS to build on previous data reported for MICVO monotherapy, ORR of~50% for n=6 R/M HNSCC (see note here). 
 
We have updated our model to reflect our growing conviction around MICVO and its potential to be a competitive treatment option for R/M HNSCC. This has resulted in our PT increasing to $8 (from $5), while reiterating our OW/Vol. rating.

Guggenheim⬆️ $PYXS&#39;s PT to $7 from $5, reiterated at a Buy, and said, PYXS&#39; planned 4Q25 MICVO phase 1 data update is now going to be more robust and answer important investor questions about its competitive positioning in HNSCC. 
$MRK $CRBP 
Guggenheim went on to say:

StockTwits Web

Pyxis Oncology Inc

Merck & Co Inc

Corbus Pharmaceuticals Holdings Inc

Quantumup

Bicara Therapeutics

Gilead Sciences, Inc.

Nanobiotix - ADR

 $8: Micvotabart Pelidotin (MICVO) Phase 1/2 R/M HNSCC Data Preview 


 CRBP 
 
PYXS expects to present preliminary data for their stroma targeting ADC MICVO formerly (PYX-201) by YE25. 
 
Data and clinical updates expected for the following: 
(1) preliminary data from Phase 1 monotherapy dose expansion study in 2L/3L R/M HNSCC patients (post-platinum based chemo & anti-PD(L)-1 and post-EGFR & anti PD(L)-1 arms), 
(2) preliminary data from Phase 1/2 combination dose escalation study of MICVO & KEYTRUDA in 1L/2L+ R/M HNSCC patients, and 
(3) next steps in the clinical development plan for MICVO for R/M HNSCC. 
 
We expect PYXS to build on previous data reported for MICVO monotherapy, ORR of~50% for n=6 R/M HNSCC (see note here). 
 
We have updated our model to reflect our growing conviction around MICVO and its potential to be a competitive treatment option for R/M HNSCC. This has resulted in our PT increasing to $8 (from $5), while reiterating our OW/Vol. rating.